The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies

Similar Items

• Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
  by: Amira Osman, et al.
  Published: (2018-04-01)
• FDA’s Strategies to Close the Health Equity Gap among Diverse Populations
  by: Jovonni Spinner, et al.
  Published: (2021-03-01)
• FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
  by: Lawrence X. Yu, et al.
  Published: (2019-12-01)
• Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?
  by: Norman J. Kachuck
  Published: (2011-11-01)
• The FDA’s Diverse and Dynamic Activities in the Social and Behavioral Sciences: Advancing and Supporting Health Equity
  by: Christine Lee, et al.
  Published: (2021-03-01)